Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols

Protocols

EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.

Contents

Title Abstract Investigator
Pattern of antioxidant and DNA repair gene expression in normal airway epithelium associated with lung cancer diagnosis. In previous studies, we reported that key antioxidant and DNA repair genes are regulated differently in normal bronchial epithelial cells of lung cancer cases ... Blomquist, Thomas
Pentraxin-3 is a novel biomarker of lung carcinoma PURPOSE: Our objective was to validate the performance of three new candidate lung cancer biomarkers, pentraxin-3 (PTX3), human kallikrein 11 (KLK11), and ... Diamandis, Eleftherios P.
Phase II Validation of a New Panel of Biomarkers for Early Detection of Ovarian Cancer While all cancer patients could potentially benefit from earlier detection and prevention, the development of new screening technologies and chemoprevention ... Mor, Gil
Polyp Prediction Study Meltzer, Stephen
Pre-Validation of Metabolomic Biomarkers of Prostate Cancer Chinnaiyan, Arul M.
Preliminary Clinical Characterization of Serum Biomarkers for Colorectal Neoplasms Brenner, Dean
Preliminary Validation of Biomarkers for the Detection of Colorectal Adenomas (Team Project #1) 1   AIMS We propose a GI Collaborative biomarker validation project with the goal of identifying those biomarkers developed by the GI collaborative that will ... Brenner, Dean
Presence of simian virus 40 DNA sequences in human Lymphoma specimens were collected and analyzed for the presence of SV40 sequences. The DMCC analyzed data for Adi Gazdar Gazdar, Adi
Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. BACKGROUND: A blood test for non-small cell lung cancer (NSCLC) may be a valuable tool for use in a comprehensive lung cancer screening strategy. Here we ... Zhong, Li
Prognostic Markers in Lynch Syndrome Colorectal Cancers Lynch, Henry
Prostate Active Surveillance Study This is a multi-center, prospective active surveillance study with selective intervention in patients with previously untreated, clinically localized prostate ... Lin UW, Daniel W.
Prostate Rapid Pre-Validation Set Determine which markers move to validation using the prospectie prostate reference set samples. Sanda, Martin
Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006) Diamandis, Eleftherios P.
Prostate Rapid Reference Set Application: Haab - Van Andel (2006) To evaluate TSP-1 as a marker to specifically detect prostate cancer Haab, Brian
Prostate Rapid Reference Set Application: Chan/Beckman Coulter (2007) Evaluate performance of [-2]proPSA as an early detection marker for prostate cancer Chan, Daniel
Prostate Rapid Reference Set: Getzenberg - Johns Hopkins (2006) Analyze marker EPCA2 on 123 observations (60 prostate cancers and 63 non-prostate cancers) Getzenberg, Robert H.
Prostate Specimen Ref Set Applicant: Isaacs-JHU-2010 Can SNP genotyping assist in the prediction of biopsy results for prostate cancer. Isaacs, William
Prostate Upgrading Team Project Aim 1: We will develop a risk assessment tool using commonly-collected clinical information from a series of contemporary radical prostatectomies to predict ... Thompson, Ian M.
Prostate-Specific Glycoproteins for Early Detection of Prostate Cancer Zhang, Hui L.
Protein profiling for detection of high risk breast cancer Semmes, John
Proteomic Approach for Diagnostic Applications in Head and Neck Cancer To evaluate the test characteristics of a panel of biomarkers for identifying patients with early stage head and neck squamous cell carcinoma (HNSCC). The ... Tainsky, Michael A.
Proteomic Data Resources for EDRN Ovary Cancer Researchers within the EDRN This project will generate a highly valuable data resource and make it available to all EDRN ovarian cancer researchers. The resource will include ... McIntosh, Martin
Proteomic Genetic and Longitudinal Pathways to Ovarian Cancer Biomarkers Discovery and verification of early detection ovarian cancer plasma/serum biomarkers. Skates, Steven
Proteomic Profiling of Serum and Other Body Fluids for the Early Detection of Colon Cancers Semmes, John
Proteomics Biomarker Development Laboratory The Biomarker Development Laboratory is focused on the application of a proteomic approach for the development of cancer biomarkers. The laboratory will apply ... Not listed
Protocol for Comparing Promoter Hypermethylation Methods in NSCLC Tockman, Melvyn S.
Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer Lung carcinoma development is accompanied by field changes that may have diagnostic significance. We have previously shown the importance of chromosomal ... Garcia, Marileila Varella
Release of Set Aside Funds - microRNA Biomarkers for Renal Cell Carcinoma Thompson, Ian M.
Research Depository of Normal and Neoplastic Human Tissues Gazdar, Adi
S-adenosylmethionine as a biomarker for the early detection of lung cancer BACKGROUND: S-Adenosylmethionine (AdoMet) is a major methyl donor for transmethylation reactions and propylamine donor for the biosynthesis of polyamines in ... Greenberg, Alissa K.
2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.